{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T15:11:28Z","timestamp":1769958688607,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CORPG3J0031"],"award-info":[{"award-number":["CORPG3J0031"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Metformin use in pregnancy is controversial because metformin crosses the placenta and the safety on the fetus has not been well-established. This retrospective study aimed to compare pregnancy outcomes in women with preexisting type 2 diabetes receiving metformin or standard insulin treatment.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The cohort of this population-based study includes women of age 20\u201344\u2009years with preexisting type 2 diabetes and singleton pregnancies in Taiwan between 2003 and 2014. Subjects were classified into three mutually exclusive groups according to glucose-lowering treatments received before and after becoming pregnant: insulin group, switching group (metformin to insulin), and metformin group. A generalized estimating equation model adjusted for patient age, duration of type 2 diabetes, hypertension, hyperlipidemia, retinopathy, and aspirin use was used to estimate the adjusted odds ratio (aOR) and 95% confidence interval (CI) of adverse pregnancy outcomes.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 1166 pregnancies were identified in the insulin group (<jats:italic>n<\/jats:italic>\u2009=\u2009222), the switching group (<jats:italic>n<\/jats:italic>\u2009=\u2009318) and the metformin group (<jats:italic>n<\/jats:italic>\u2009=\u2009626). The insulin group and the switching group had similar pregnancy outcomes for both the mother and fetus, including risk of primary cesarean section, pregnancy-related hypertension, preeclampsia, preterm birth (&lt;\u200937\u2009weeks), very preterm birth (&lt;\u200932\u2009weeks), low birth weight (&lt;\u20092500\u2009g), high birth weight (&gt;\u20094000\u2009g), large for gestational age, and congenital malformations. The metformin group had a lower risk of primary cesarean section (aOR\u2009=\u20090.57; 95% CI, 0.40\u20130.82) and congenital malformations (aOR, 0.51; 95% CI; 0.27\u20130.94) and similar risk for the other outcomes as compared with the insulin group.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Metformin therapy was not associated with increased adverse pregnancy outcomes in women with type 2 diabetes as compared with standard insulin therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12884-020-03207-0","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T18:02:48Z","timestamp":1599242568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Association of pregnancy outcomes in women with type 2 diabetes treated with metformin versus insulin when becoming pregnant"],"prefix":"10.1186","volume":"20","author":[{"given":"Shu-Fu","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shang-Hung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Fu","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Jiun","family":"Chiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3224-7238","authenticated-orcid":false,"given":"Yu-Tung","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,4]]},"reference":[{"key":"3207_CR1","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.beem.2010.05.011","volume":"24","author":"R Temple","year":"2010","unstructured":"Temple R, Murphy H. Type 2 diabetes in pregnancy - an increasing problem. Best Pract Res Clin Endocrinol Metab. 2010;24:591\u2013603.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"3207_CR2","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1111\/j.1464-5491.2005.01784.x","volume":"22","author":"JM Roland","year":"2005","unstructured":"Roland JM, Murphy HR, Ball V, et al. The pregnancies of women with type 2 diabetes: poor outcomes but opportunities for improvement. Diabet Med. 2005;22:1774\u20137.","journal-title":"Diabet Med"},{"key":"3207_CR3","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.2337\/dc19-S014","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. Management of diabetes in pregnancy: standards of medical care in diabetes\u20132019. Diabetes Care. 2019;42:S165\u201372.","journal-title":"Diabetes Care"},{"key":"3207_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/2042098618769831","volume":"9","author":"TM Polasek","year":"2018","unstructured":"Polasek TM, Doogue MP, Thynne TRJ. Metformin treatment of type 2 diabetes mellitus in pregnancy: update on safety and efficacy. Ther Adv Drug Saf. 2018;9:287\u201395.","journal-title":"Ther Adv Drug Saf"},{"key":"3207_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2337\/dc09-1184","volume":"33","author":"AJ Karter","year":"2010","unstructured":"Karter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care. 2010;33:733\u20135.","journal-title":"Diabetes Care"},{"key":"3207_CR6","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854\u201365.","journal-title":"Lancet."},{"key":"3207_CR7","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577\u201389.","journal-title":"N Engl J Med"},{"key":"3207_CR8","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.2337\/dc19-S009","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142019. Diabetes Care. 2019;42:S90\u2013102.","journal-title":"Diabetes Care"},{"key":"3207_CR9","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1210\/jcem.87.2.8207","volume":"87","author":"DJ Jakubowicz","year":"2002","unstructured":"Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:524\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"3207_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00431-008-0737-7","volume":"168","author":"S Bolton","year":"2009","unstructured":"Bolton S, Cleary B, Walsh J, et al. Continuation of metformin in the first trimester of women with polycystic ovarian syndrome is not associated with increased perinatal morbidity. Eur J Pediatr. 2009;168:203\u20136.","journal-title":"Eur J Pediatr"},{"key":"3207_CR11","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1210\/jc.2011-3061","volume":"97","author":"L Morin-Papunen","year":"2012","unstructured":"Morin-Papunen L, Rantala AS, Unkila-Kallio L, et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. J Clin Endocrinol Metab. 2012;97:1492\u2013500.","journal-title":"J Clin Endocrinol Metab"},{"key":"3207_CR12","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1056\/NEJMoa0707193","volume":"358","author":"JA Rowan","year":"2008","unstructured":"Rowan JA, Hague WM, Gao W, et al. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358:2003\u201315.","journal-title":"N Engl J Med"},{"key":"3207_CR13","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S2213-8587(15)00219-3","volume":"l3","author":"C Chiswick","year":"2015","unstructured":"Chiswick C, Reynolds RM, Denison F, et al. Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrino. 2015;l3:778\u201386.","journal-title":"Lancet Diabetes Endocrino"},{"key":"3207_CR14","doi-asserted-by":"publisher","first-page":"k2477","DOI":"10.1136\/bmj.k2477","volume":"361","author":"JE Given","year":"2018","unstructured":"Given JE, Loane M, Garne E, et al. Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study. BMJ. 2018;361:k2477.","journal-title":"BMJ."},{"key":"3207_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/01.ftd.0000184161.52573.0e","volume":"28","author":"B Charles","year":"2006","unstructured":"Charles B, Norris R, Xiao X, et al. Population pharmacokinetics of metformin in late pregnancy. Ther Drug Monit. 2006;28:67\u201372.","journal-title":"Ther Drug Monit"},{"key":"3207_CR16","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1007\/s00125-017-4351-y","volume":"60","author":"RS Lindsay","year":"2017","unstructured":"Lindsay RS, Loeken MR. Metformin use in pregnancy: promises and uncertainties. Diabetologia. 2017;60:1612\u20139.","journal-title":"Diabetologia."},{"key":"3207_CR17","unstructured":"The National Diabetes Services Scheme (NDSS; administered by Diabetes Australia). Having a healthy baby guide for women with type 2 diabetes. Available: https:\/\/www.ndss.com.au\/about-diabetes\/resources\/find-a-resource\/having-a-healthy-baby-guide-for-women-with-type-2-diabetes. Accessed 2020 April 11."},{"key":"3207_CR18","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1001\/jamainternmed.2015.3540","volume":"175","author":"AW Hsing","year":"2015","unstructured":"Hsing AW, Ioannidis JP. Nationwide population science: lessons from the Taiwan National Health Insurance research database. JAMA Intern Med. 2015;175:1527\u20139.","journal-title":"JAMA Intern Med"},{"key":"3207_CR19","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jama.2017.13883","volume":"318","author":"SH Chang","year":"2017","unstructured":"Chang SH, Chou IJ, Yeh YH, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA. 2017;318:1250\u20139.","journal-title":"JAMA."},{"key":"3207_CR20","first-page":"297","volume":"103","author":"CM Lin","year":"2004","unstructured":"Lin CM, Lee PC, Teng SW, et al. Validation of the Taiwan birth registry using obstetric records. J Formos Med Assoc. 2004;103:297\u2013301.","journal-title":"J Formos Med Assoc"},{"key":"3207_CR21","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1007\/s40265-017-0823-0","volume":"77","author":"A Atallah","year":"2017","unstructured":"Atallah A, Lecarpentier E, Goffinet F, et al. Aspirin for prevention of preeclampsia. Drugs. 2017;77:1819\u201331.","journal-title":"Drugs."},{"key":"3207_CR22","doi-asserted-by":"publisher","first-page":"396","DOI":"10.2337\/dci18-0055","volume":"42","author":"LA Barbour","year":"2019","unstructured":"Barbour LA, Feig DS. Metformin for gestational diabetes mellitus: progeny, perspective, and a personalized approach. Diabetes Care. 2019;42:396\u20139.","journal-title":"Diabetes Care"},{"key":"3207_CR23","first-page":"B2","volume":"218","author":"Society of Maternal-Fetal Medicine (SMFM) Publications Committee","year":"2018","unstructured":"Society of Maternal-Fetal Medicine (SMFM) Publications Committee. SMFM statement: pharmacological treatment of gestational diabetes. Am J Obstet Gynecol. 2018;218:B2\u20134.","journal-title":"Am J Obstet Gynecol"},{"key":"3207_CR24","unstructured":"National Institute for Health and Care Excellence (NICE). Diabetes in pregnancy: management from preconception to the postnatal period. NICE guideline NG3. Available from https:\/\/www.nice.org.uk\/guidance\/ng3. Accessed 19 March 2019."},{"issue":"Suppl 3","key":"3207_CR25","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.1016\/S0020-7292(15)30033-3","volume":"131","author":"M Hod","year":"2015","unstructured":"Hod M, Kapur A, Sacks DA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on gestational diabetes mellitus: a pragmatic guide for diagnosis, management, and care. Int J Gynaecol Obstet. 2015;131(Suppl 3):S173\u2013211.","journal-title":"Int J Gynaecol Obstet"},{"issue":"Suppl 1","key":"3207_CR26","doi-asserted-by":"publisher","first-page":"S255","DOI":"10.1016\/j.jcjd.2017.10.038","volume":"42","author":"DS Feig","year":"2018","unstructured":"Feig DS, Berger H, Donovan L, et al. Diabetes and pregnancy. Can J Diabetes. 2018;42(Suppl 1):S255\u201382.","journal-title":"Can J Diabetes"},{"key":"3207_CR27","unstructured":"Sable-Smith B. Americans going to Mexico to buy insulin at fraction of US cost. Medscape Feb 15, 2019. Available from https:\/\/www.medscape.com\/viewarticle\/909174. Accessed 19 March 2019."},{"key":"3207_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2017-000456","volume":"6","author":"JA Rowan","year":"2018","unstructured":"Rowan JA, Rush EC, Plank LD, et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age. BMJ Open Diabetes Res Care. 2018;6:e000456.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"3207_CR29","doi-asserted-by":"publisher","first-page":"E448","DOI":"10.1210\/jc.2010-0853","volume":"95","author":"E Vanky","year":"2010","unstructured":"Vanky E, Stridsklev S, Heimstad R, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab. 2010;95:E448\u201355.","journal-title":"J Clin Endocrinol Metab"},{"key":"3207_CR30","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1210\/jc.2017-02419","volume":"103","author":"LG Engen Hanem","year":"2018","unstructured":"Engen Hanem LG, Stridsklev S, J\u00fal\u00edusson PB, et al. Metformin use in PCOS pregnancies increases the risk of offspring overweight at 4 years of age: follow-up of two RCTs. J Clin Endocrinol Metab. 2018;103:1612\u201321.","journal-title":"J Clin Endocrinol Metab"},{"key":"3207_CR31","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.2337\/dc07-0278","volume":"30","author":"A Guerin","year":"2007","unstructured":"Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes. Diabetes Care. 2007;30:1920\u20135.","journal-title":"Diabetes Care"},{"key":"3207_CR32","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/sj.ijo.0801670","volume":"25","author":"NJ Sebire","year":"2001","unstructured":"Sebire NJ, Jolly M, Harris JP, et al. Maternal obesity and pregnancy outcome: a study of 287,213 pregnancies in London. Int J Obes Relat Metab Disord. 2001;25:1175\u201382.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"3207_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/dme.13150","volume":"34","author":"S Butalia","year":"2017","unstructured":"Butalia S, Gutierrez L, Lodha A, et al. Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis. Diabet Med. 2017;34:27\u201336.","journal-title":"Diabet Med"},{"key":"3207_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/sj.ijo.0803695","volume":"32","author":"A Golay","year":"2008","unstructured":"Golay A. Metformin and body weight. Int J Obes. 2008;32:61\u201372.","journal-title":"Int J Obes"},{"key":"3207_CR35","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1001\/jama.2014.5951","volume":"311","author":"A Wallia","year":"2014","unstructured":"Wallia A, Molitch ME. Insulin therapy for type 2 diabetes mellitus. JAMA. 2014;311:2315\u201325.","journal-title":"JAMA."},{"key":"3207_CR36","first-page":"397","volume":"57","author":"KM Knight","year":"2012","unstructured":"Knight KM, Thornburg LL, Pressman EK. Pregnancy outcomes in type 2 diabetic patients as compared with type 1 diabetic patients and nondiabetic controls. J Reprod Med. 2012;57:397\u2013404.","journal-title":"J Reprod Med"},{"key":"3207_CR37","doi-asserted-by":"publisher","first-page":"361435","DOI":"10.1155\/2013\/361435","volume":"2013","author":"B Groen","year":"2013","unstructured":"Groen B, Links TP, van den Berg PP, et al. Similar adverse pregnancy outcome in native and nonnative dutch women with pregestational type 2 diabetes: a multicentre retrospective study. ISRN Obstet Gynecol. 2013;2013:361435.","journal-title":"ISRN Obstet Gynecol"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-020-03207-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-020-03207-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-020-03207-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T23:50:58Z","timestamp":1630713058000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-020-03207-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3207"],"URL":"https:\/\/doi.org\/10.1186\/s12884-020-03207-0","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,4]]},"assertion":[{"value":"3 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective cohort study was approved by the Institutional Review Board (IRB) of Chang Gung Memorial Hospital in Taiwan (IRB number: 201800556B0) and was conducted in accordance with the ethical principles. The IRB waived the requirement of patient informed consent due to the anonymized nature of these datasets.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"512"}}